MedTrace Logo

An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

NCT01325402 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-12-10

No results posted yet for this study

Summary

In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress and treatment effects.

Conditions

  • Maximum Diagnostic Mass of [18Fluor]AZD4694

Interventions

OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 40 and 50 ug.

OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 20 ug.

OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.

Sponsors & Collaborators

Principal Investigators

  • Bjorn Paulsson · AstraZeneca

  • Niels Andreasen, MD · Geriatric clinic Karolinska University Hospital Huddinge

  • Elisabeth Eden, MD · Quintiles Aktiebolag

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01325402 on ClinicalTrials.gov